EN DE
Watch Scienture Holdings, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Scienture Holdings, Inc. (SCNX) fair value: what the stock is really worth

As of Oct 16, 2026: fair value (intrinsic value) of Scienture Holdings, Inc. stock $3.68, price $3.36, upside +9.4%, quality 39 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US80880X1046

SH Scienture Holdings, Inc. logo Thin data Oct 3, 2026

Scienture Holdings, Inc.

SCNX · US

Low PriorityFair Value upside is limited and quality is weak.

The stock costs about what our calculation considers fair.

Low debt
Fair value $3.68 · Fairly valued (+9.4%)
Mixed vs. peers (4/7)
Quality 39/100
Weak Growth (revenue 5y −52.1 %/yr in USD)
Negative free cash flow
Narrow moat 2/100 · thin data
Thin data
Watch Scienture Holdings, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1,329 $3.24 Fair Value $3.68 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range $3.24 – $1,329 · fair‑value band $2.82 – $4.68 · the $3.36 price screens below the $3.68 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 3, 2026.

Follow Scienture Holdings in your weekly email

Every Wednesday you see whether Scienture Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.

Show moreShow less

The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.

It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia.

Scienture Holdings, Inc. is headquartered in Commack, New York.

Stock analysis

Scienture Holdings, Inc. (SCNX) currently trades at $3.36, while our model-based Fair Value estimate is $3.68, so the stock looks roughly fairly valued today (gap 8.6%).

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $2.82 (bear) to $4.68 (bull), the price of $3.36 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Scienture Holdings, Inc. reported revenue of $432K in FY2025 versus $9.9M in FY2021, a compound −54.3%/yr. Reported net income was −$41.5M in FY2025.

Key figures

Market cap $261K Micro · P/S ratio 0.32 · EPS (TTM) $−50.75 · Return on equity −53.5% · Return on assets (EBIT) −47.8% · Operating margin −786% · Revenue (TTM) $821K · Revenue growth (YoY) +449%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 2 out of 100 (low confidence).

What moves the price

The share trades about 95% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 9%, SCNX screens richer than that median.

Fair Value models

Bear $2.82 Fair Value $3.68 Bull $4.68
Price $3.36 · Upside +9.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings $0.1126 $0.1470 $0.1872 78
EV/EBITDA $0.1572 $0.2095 $0.2618 67
All 2 models by family
DCF Models
Owner Earnings $0.1126 $0.1470 $0.1872 78
Multiples
EV/EBITDA $0.1572 $0.2095 $0.2618 67

The fair value above starts from this blend and is adjusted for a stock split.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 39/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 70
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 56
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 2
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−65.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−52.1%
Start year 2020 (pandemic). Over 10 years: −17.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.6% (2020) → −3,763.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch SCNX, get fair value alerts →

Compare Scienture Holdings, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 55 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 39 · Bottom 25%
Fair Value upside +9.4% · Above median
Profitability
Return on assets −49.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 449.1% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper

P/S (12 months) 0.34× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)46 · sector 45
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)0 · sector 24
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 70

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Yifeng Pharmacy Chain Co 603939 ¥25.08 ¥40.59 +62% vs SCNX
Luyan Pharma Co 002788 ¥10.76 ¥15.91 +48% vs SCNX
DaShenLin Pharmaceutical Group 603233 ¥18.61 ¥26.45 +42% vs SCNX
LBX Pharmacy Chain Joint Stock Company 603883 ¥13.04 ¥14.34 +10% vs SCNX
Anhui Huaren Health Pharmaceutical Co 301408 ¥14.93 ¥16.42 +10% vs SCNX
Yixintang Pharmaceutical Group 002727 ¥10.72 ¥9.51 −11% vs SCNX
Cachet Pharmaceutical Co 002462 ¥12.26 ¥9.94 −19% vs SCNX
MedPlus Health Services Limited MEDPLUS ₹654.30 ₹393.38 −40% vs SCNX
Apotea AB APOTEA kr 85.25 kr 46.46 −46% vs SCNX
ShuYu Civilian Pharmacy Corp 301017 ¥14.84 ¥5.91 −60% vs SCNX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Scienture Holdings, Inc. · Fair Value
$3.68 +9%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Scienture Holdings, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/SCNX

Frequently asked questions

Is Scienture Holdings, Inc. (SCNX) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $3.68 versus a price of $3.36, about +9% upside (fairly valued).
What is the fair value of SCNX?
Our model-based fair value for Scienture Holdings, Inc. is $3.68 (as of Oct 3, 2026), built from audited fundamentals. The current price: $3.36.
What is the quality score of SCNX?
Scienture Holdings, Inc. has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Scienture Holdings, Inc. (SCNX)?
Our model-based price target is the fair value of $3.68 (as of Oct 3, 2026) from 2 valuation models. Cautious scenario $2.82, optimistic scenario $4.68. It is a calculation from audited fundamentals, not an analyst target.
What is the Scienture Holdings, Inc. stock forecast for 2026?
Our models put fair value at $3.68, about +9% upside versus a price of $3.36 (fairly valued). Cautious scenario $2.82, optimistic scenario $4.68. The calculation is refreshed regularly with new filings.
What is the revenue of Scienture Holdings, Inc. (SCNX)?
Scienture Holdings, Inc. reported trailing-twelve-month revenue of about $821K (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Scienture Holdings, Inc. (SCNX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Scienture Holdings, Inc. it is $3.68 per share (as of Oct 3, 2026), against a price of $3.36. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Scienture Holdings, Inc. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, SCNX trades below its calculated fair value: price $3.36, fair value $3.68, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SCNX?
No. The price is what the market pays today ($3.36); the fair value is what the company's own numbers justify ($3.68). For Scienture Holdings, Inc. the two are $0.3150 per share apart. That gap is exactly why we show both numbers side by side.
How much is Scienture Holdings, Inc. worth?
The market values Scienture Holdings, Inc. at about $261K (market capitalisation, as of Oct 3, 2026). Per share that is $3.36; our models calculate a fair value of $3.68 per share.
What do the bullish and bearish scenarios say about SCNX?
Our models span a range for Scienture Holdings, Inc.: cautious scenario $2.82, base $3.68, optimistic $4.68 per share (as of Oct 3, 2026, price $3.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Scienture Holdings, Inc. (SCNX)?
Balance-sheet figures for Scienture Holdings, Inc. (as of Oct 3, 2026): return on equity −53.5%, debt of 0.01 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is SCNX from its 52-week high?
Scienture Holdings, Inc. trades at $3.36, about 95% below its 52-week high of $65.00 and 4% above the low of $3.24 (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of $3.68 is for.
Which stocks are comparable to Scienture Holdings, Inc.?
From the same area (Healthcare) we also value Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, Yixintang Pharmaceutical Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Scienture Holdings, Inc. stock attractive at the current price?
The data as of Oct 3, 2026: price $3.36, calculated fair value $3.68 (+9%), Quality Score 39/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SCNX calculated?
We run Scienture Holdings, Inc. through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.68, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.8 % above its aggregate fair value. Scienture Holdings, Inc. currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Scienture Holdings, Inc. (SCNX)?
The closing price on Oct 16, 2026 was $3.36. Our model-based fair value is $3.68, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Scienture Holdings, Inc. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Scienture Holdings, Inc.

How large is the market capitalisation of Scienture Holdings, Inc. (SCNX)?
The market capitalisation of Scienture Holdings, Inc. is $261K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Scienture Holdings, Inc. (SCNX)?
The price-to-sales ratio of Scienture Holdings, Inc. is 0.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Scienture Holdings, Inc. (SCNX)?
Earnings per share at Scienture Holdings, Inc. are $−50.75. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Scienture Holdings, Inc. (SCNX)?
The return on equity (ROE) of Scienture Holdings, Inc. is −53.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Scienture Holdings, Inc. (SCNX)?
On an EBIT basis the return on assets of Scienture Holdings, Inc. is −47.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Scienture Holdings, Inc. (SCNX)?
The operating margin of Scienture Holdings, Inc. is −786% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Scienture Holdings, Inc. (SCNX)?
Revenue at Scienture Holdings, Inc. is growing +449% versus a year earlier (3y avg −65.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Scienture Holdings, Inc. (SCNX) generate?
The free cash flow of Scienture Holdings, Inc. is −$13.4B (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Scienture Holdings, Inc. (SCNX) hold?
Scienture Holdings, Inc. holds more cash than debt, $6.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Scienture Holdings, Inc. in the live analysis

One click puts Scienture Holdings, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.